Multiphase experiments with at least one later laboratory phase. II. Nonorthogonal designs
نویسندگان
چکیده
منابع مشابه
Randomized phase II designs.
As the use of molecularly targeted agents, which are anticipated to increase overall survival (OS)and progression-free survival (PFS) but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such designs reduce the potential for bias, existent in comparisons with historical controls, but ...
متن کاملRandomized phase II trial designs with biomarkers.
Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proce...
متن کامل“At least one” caching
We consider a variant of the caching problem, where each request is a set of pages of a fixed size, instead of a single page. In order to serve such a request, we require at least one of those pages to be present in the cache. Each page is assumed to have unit size and unit cost for getting loaded into the cache. We prove lower bounds on the competitive ratio for this problem in both the determ...
متن کاملIdentifying appropriate phase II trial designs
The phase II to III transition in the drug development process is associated with the highest risk compared to transition rates between other phases [1]. With increasing pressure to improve efficiency in this process it is essential that phase II trials are designed based on informed decisions, and to provide reliable results. With over 120 different phase II trial designs available [2], identi...
متن کاملAdaptive designs for Phase II oncology trials
The role of Phase II trials in oncology drug development Traditionally, Phase II in oncology drug development acts as a screening tool by identifying treatments with sufficient activity that warrant further investigation in large and costly Phase III studies. However, Phase II has also another more prominent role in cancer research as there is a significant number of drugs that were approved ba...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Australian & New Zealand Journal of Statistics
سال: 2019
ISSN: 1369-1473,1467-842X
DOI: 10.1111/anzs.12260